John B.A.G. Haanen
0000-0001-5884-7704
Publication & Citation Trends
Most Cited Works
Publications
927 total
Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies OA
Cited by 8
Semantic Scholar
Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation. OA
Cited by 8
Semantic Scholar
Sex differences in the pharmacokinetics of anticancer drugs: a systematic review
Cited by 23
Semantic Scholar
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Cited by 1,039
OpenAlex
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers PDF
Cited by 1,358
OpenAlex
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma PDF
Cited by 3,651
OpenAlex
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma PDF
Cited by 2,506
OpenAlex
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma PDF
Cited by 1,342
OpenAlex
Research Topics
Cancer Immunotherapy and Biomarkers
(421)
CAR-T cell therapy research
(378)
Immunotherapy and Immune Responses
(261)
Melanoma and MAPK Pathways
(156)
Cutaneous Melanoma Detection and Management
(124)
Frequent Co-Authors
Affiliations
Leiden University
Université Libre de Bruxelles
Royal Marsden NHS Foundation Trust
University Medical Center Groningen
The University of Texas MD Anderson Cancer Center